suma/infarction

TECHNOLOGICAL FIELD This invention relates to amines represented by general formula (1). More specifically, it relates to an amine represented by general formula (1) or its pharmaceutically acceptable acid addition salt or quaternary ammonium salt, and a drug containing it as an active ingredient,

BACKGROUND OF THE INVENTION The present invention relates to the use of 4-chloro-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-methoxy-2-methyl-pyri- midine (=moxonidine) and its physiologically compatible acid addition salts for the treatment of myocardial damage secondary to myocardial infarction and

BACKGROUND OF THE INVENTION Since atherosclerotic coronary heart disease is the single greatest cause of death in the United States, the need to provide a means to prevent myocardial infarction or to at least reduce the size of any infarct after a coronary occlusion occurs has resulted in

BACKGROUND Myocardial infarction (MI), commonly known as heart attack, is associated with modifiable risk factors but nonetheless remains a leading cause of death and severe disability worldwide. (Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with MI in

BACKGROUND OF THE INVENTION Filed of the Invention The present invention relates generally to the fields intravenous administration of drug combinations and medical devices. More specifically, the present invention is directed to devices and methods that enable simultaneous administration of

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to a method for administering protein phosphatase inhibitors to an individual to diminish myocardial infarction and minimize cell injury or death in ischemic tissue. Specifically, the present invention

The present invention relates to imidazole derivatives and salts thereof, to their synthesis and intermediates therefor, to pharmaceutical formulations containing such compounds and to the use of these compounds in medicine. Thromboxane A.sub.2 (TXA.sub.2), a potent stimulator of blood platelet

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. National Stage of International Application No. PCT/KR2011/006065, filed Aug. 18, 2011, which claims priority to and the benefit of Korean Patent Application No. 10-2010-0079857, filed Aug. 18, 2010, which is hereby incorporated by

BACKGROUND OF THE INVENTION This invention relates to the treatment of myocardial infarction and more particularly to a therapy capable of preventing the reocclusion of a coronary artery which often accompanies the use of thrombolytic agents in the treatment of myocardial infarction. This invention

PRIORITY TO RELATED APPLICATIONS(S) This application claims the benefit of European Patent Application No. 08150173.6, filed Jan. 11, 2008, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Alzheimer's disease (AD) is the most common cause of dementia in later

TECHNICAL FIELD This invention relates to novel diamine compounds and acid addition salts thereof and cerebral protective drugs containing the compounds or their salts, and more particularly to diamine compounds and acid addition salts thereof which have an excellent cerebral protective action and

This application is a 371 of PCT/JP95/00254 filed Feb. 22, 1995. BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel aminoalkylcyclopropane derivative having an antagonistic activity with respect to N-methyl-D-aspartic acid (hereinbelow, referred to as

BACKGROUND OF THE INVENTION Cardiovascular diseases are a leading cause of death resulting in almost 40% of deaths annually in the United States. Inadequate human myocardial regeneration poses a significant public health problem. It is estimated that 13 million Americans have coronary artery

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is concerned with substituted piperazine compounds, therapeutic dosage forms including one or more of the compounds, and methods for treating diseases in mammals, and in particular, in a human in a therapy selected from the

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is concerned with substituted piperazine compounds, therapeutic dosage forms including one or more of the compounds, and methods for treating diseases in mammals, and in particular, in a human in a therapy selected from the